DC

Defilade Capital Management, L.P.

High-turnover traderSector-focusedContrarian

Total reported value

$712.2M

Reporting period: 2026-03-31 · Number of holdings: 31

Defilade Capital Management, L.P. disclosed 31 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $712.2M and a quarterly turnover rate of 98.7%.

Personality snowflake

Concentration
16.5
Portfolio Stability
98.69
Momentum/Contrarian
0
Sector conviction
100
Diversification
62
Sizing Uniformity
94.63

Recent moves

  • Trim PFE

    -33.6%　-$35.5M

  • Add BDX

    +243.8%　$28.1M

  • Add INSM

    +289.8%　$23.2M

  • Add HSIC

    +94.8%　$21.8M

  • Add DXCM

    +120.0%　$17.6M

  • Trim PACS

    -47.3%　-$18.3M

Holdings Map

New buyAddUnchangedTrim

Top 10 holdings by weight

Full holdings list this quarter

#TickerIssuerAsset SubclassWeightWeight ChangeShares Change4Q Trend
1ZBHZimmer Biomet Holdings INCStock-Healthcare7.35%+7.35%NEW
2HSICHenry Schein INCStock-Healthcare6.46%+3.18%+94.75%
3BDXBecton Dickinson And CoStock-Healthcare6.16%+4.02%+243.82%
4PTCTPtc Therapeutics INCStock-Healthcare5.77%+5.77%NEW
5DXCMDexcom INCStock-Healthcare4.75%+2.55%+120.01%
6ICUIIcu Medical INCStock-Other4.61%-1.98%-25.37%
7INSMInsmed INCStock-Healthcare4.48%+3.30%+289.82%
8ISRGIntuitive Surgical INCStock-Healthcare4.38%+0.87%+48.22%
9RVMDRevolution Medicines INCStock-Healthcare4.31%+0.39%-13.06%
10GMEDGlobus Medical INC - AStock-Healthcare4.29%+1.13%+32.61%
11NBIXNeurocrine Biosciences INCStock-Healthcare3.88%+3.88%NEW
12DNLIDenali Therapeutics INCStock-Other3.67%+2.20%+107.09%
13PACSPacs Group INCStock-Other3.60%-2.36%-47.26%
14OLMAOlema Pharmaceuticals INCStock-Other3.15%-1.03%+21.86%
15ELANElanco Animal Health INCStock-Healthcare3.13%+1.90%+132.04%
16PFEPfizer INCStock-Healthcare2.72%-4.72%-33.55%
17LLYEli Lilly & CoStock-Healthcare2.67%-1.98%-35.22%
18LNTHLantheus Holdings INCStock-Healthcare2.66%+2.66%NEW
19ITGRInteger Holdings CORPStock-Healthcare2.63%+2.63%NEW
20BIIBBiogen INCStock-Healthcare2.48%-1.38%-40.56%
21EVMNEvommune INCStock-Other2.19%+1.69%+215.01%
22TNDMTandem Diabetes Care INCStock-Other2.05%+2.05%NEW
23COGTCogent Biosciences INCStock-Other1.91%-0.83%-37.99%
24NUVLNuvalent Inc-aStock-Other1.87%-1.80%-51.70%
25OCULOcular Therapeutix INCStock-Other1.77%+0.65%+118.24%
26ASNDAscendis Pharma A/SStock-Other1.67%-0.81%-39.44%
27ALGNAlign Technology INCStock-Healthcare1.62%-1.09%-47.42%
28ELDNEledon Pharmaceuticals INCStock-Other1.54%+0.87%+8.32%
29ORICOric Pharmaceuticals INCStock-Other1.50%+1.50%NEW
30BHVNBiohaven Ltd.Stock-Other0.38%+0.38%NEW
31MREOMereo Biopharma Group Pl-adrStock-Other0.35%+0.35%NEW

Holding changes this quarter

Defilade Capital Management, L.P.'s most significant position changes for 2026-03-31: New buy: Zimmer Biomet Holdings INC (ZBH); Sold out: Abbvie INC (ABBV); Sold out: Novartis Ag-sponsored Adr (NVS); New buy: Ptc Therapeutics INC (PTCT); Sold out: STERIS plc (STE).

Position changes disclosed by Defilade Capital Management, L.P. for the quarter ending 2026-03-31, including ticker, issuer, weight change, shares change, and action
#TickerIssuerWeight ChangeShares ChangeAction
1BDXBecton Dickinson And Co+4%+243.82%Add
2INSMInsmed INC+3.3%+289.82%Add
3HSICHenry Schein INC+3.2%+94.75%Add
4DXCMDexcom INC+2.6%+120.01%Add
5DNLIDenali Therapeutics INC+2.2%+107.09%Add
6ELANElanco Animal Health INC+1.9%+132.04%Add
7EVMNEvommune INC+1.7%+215.01%Add
8GMEDGlobus Medical INC - A+1.1%+32.61%Add
9ELDNEledon Pharmaceuticals INC+0.9%+8.32%Add
10ISRGIntuitive Surgical INC+0.9%+48.22%Add
11OCULOcular Therapeutix INC+0.7%+118.24%Add
12RVMDRevolution Medicines INC+0.4%-13.06%Trim
13ASNDAscendis Pharma A/S-0.8%-39.44%Trim
14COGTCogent Biosciences INC-0.8%-37.99%Trim
15OLMAOlema Pharmaceuticals INC-1%+21.86%Add
16ALGNAlign Technology INC-1.1%-47.42%Trim
17BIIBBiogen INC-1.4%-40.56%Trim
18NUVLNuvalent Inc-a-1.8%-51.70%Trim
19ICUIIcu Medical INC-2%-25.37%Trim
20LLYEli Lilly & Co-2%-35.22%Trim
21PACSPacs Group INC-2.4%-47.26%Trim
22PFEPfizer INC-4.7%-33.55%Trim
23ZBHZimmer Biomet Holdings INC—NEWNew buy
24ABBVAbbvie INC—EXITSold out
25NVSNovartis Ag-sponsored Adr—EXITSold out
26PTCTPtc Therapeutics INC—NEWNew buy
27STESTERIS plc—EXITSold out
28NBIXNeurocrine Biosciences INC—NEWNew buy
29XNCRXencor INC—EXITSold out
30LNTHLantheus Holdings INC—NEWNew buy
31ITGRInteger Holdings CORP—NEWNew buy
32ATRCAtricure INC—EXITSold out
33LIVNLivaNova PLC—EXITSold out
34TNDMTandem Diabetes Care INC—NEWNew buy
35ATECAlphatec Holdings INC—EXITSold out
36ORICOric Pharmaceuticals INC—NEWNew buy
37GKOSGlaukos CORP—EXITSold out
38RXSTRxsight INC—EXITSold out
39TFXTeleflex INC—EXITSold out
40CNMDConmed CORP—EXITSold out
41BHVNBiohaven Ltd.—NEWNew buy
42MREOMereo Biopharma Group Pl-adr—NEWNew buy

FAQ

What is Defilade Capital Management, L.P. and what type of investor is it?
Defilade Capital Management, L.P. is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $712.2M, spread across 31 disclosed positions.
What are Defilade Capital Management, L.P.'s largest equity positions?
Based on the latest 13F filing, Defilade Capital Management, L.P.'s top holdings by market value are: 1. Zimmer Biomet Holdings INC (ZBH) — $52.4M (7.3%) 2. Henry Schein INC (HSIC) — $46.0M (6.5%) 3. Becton Dickinson And Co (BDX) — $43.9M (6.2%) 4. Ptc Therapeutics INC (PTCT) — $41.1M (5.8%) 5. Dexcom INC (DXCM) — $33.8M (4.8%)
What changes did Defilade Capital Management, L.P. make in its most recent portfolio filing?
In the latest reported quarter, Defilade Capital Management, L.P. made 42 notable position adjustments: 9 new positions were initiated, 12 existing holdings were added to, 10 positions were partially reduced, and 11 were completely exited. The largest of these moves: New buy: Zimmer Biomet Holdings INC (ZBH); Sold out: Abbvie INC (ABBV); Sold out: Novartis Ag-sponsored Adr (NVS); New buy: Ptc Therapeutics INC (PTCT); Sold out: STERIS plc (STE)
What sectors does Defilade Capital Management, L.P. focus on?
Defilade Capital Management, L.P. is concentrated in the following sectors based on its current disclosed equity portfolio: • Health Care: 100.0%